Clinical trials: Locally Advanced Cervical Carcinoma, active
Locally Advanced Head and Neck Squamous Cell Carcinoma
Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the efficacy and safety of induction mTPF chemotherapy followed by concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck cancer
- Trial name
- NCT05527782
- Testing
- modified TPF, Quality of life assessment (QoL)
- Where
- 3 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Universitario Doctor Peset
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
To compare the effectiveness and toxicity of nedaplatin versus cisplatin in induction chemotherapy combined with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04437329
- Testing
- Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Cervical Carcinoma
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
For locally advanced cervical cancer, there are two main treatment options: One is radical chemoradiotherapy (a combination of radiotherapy and chemotherapy aimed at curing the disease).
- Trial name
- NCT07088731
- Testing
- Sintilimab, Concurrent chemo-radiotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Locally Advanced Cervical Cancer
Curcumin Supplementation in Cervical Cancer
Brief Summary. The goal of this pilot study is to learn about the effect of curcumin supplementation in locally advanced cervical cancer patients.
- Trial name
- NCT06080841
- Testing
- Curcumin, Curcumin + Piperine
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- National Institute of Cancerología
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab Plus Olaparib in LA-HNSCC
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally advanced head and neck…
- Trial name
- NCT05366166
- Testing
- Pembrolizumab, Olaparib, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
LA HNSCC
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
- Trial name
- NCT06978829
- Testing
- TP + Cetuximab + Tislelizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Esophageal Squamous Cell Carcinoma
Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy Era
This prospective observational cohort study will evaluate different radiotherapy target volume delineation patterns in patients with locally advanced esophageal squamous cell carcinoma receiving radiotherapy combined with…
- Trial name
- NCT07858630
- Testing
- GTV-CTV Longitudinal Margin, Regional Lymph Node Irradiation Strategy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Intravenously Administered PROMITIL Combined With Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients
This will be an open-label, single-arm, prospective study, in which patients requiring RT for locally and/or regionally advanced head and neck cancers will undergo a combination treatment comprised of intravenously delivered…
- Trial name
- NCT07920289
- Testing
- Addition of Promitil to External Beam Radiotherapy
- Volunteers
- 20 people
- Sponsor
- Assuta Ashdod Hospital
Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer
Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (cSCC) is typically associated with a high tumour mutation burden, with the majority caused by Ultraviolet (UV) exposure (Pickering et al., 2014).
- Trial name
- DESQUAMATE (NCT05025813)
- Testing
- Pembrolizumab
- Where
- 3 sites in Australia
- Volunteers
- 27 people
- Sponsor
- Queensland Health
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Head and Neck Squamous Cell Carcinoma, Solid Tumor
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic…
- Trial name
- NCT07232524
- Testing
- BL-M24D1
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced Cervical Carcinoma
A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
This study aims to compare the efficacy and safety of "neoadjuvant immunotherapy combined with chemotherapy followed by immunotherapy combined with radiotherapy during the radiotherapy period" versus "standard concurrent…
- Trial name
- NCT07613567
- Testing
- standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer, Advanced Cancer
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation
Patients with locally advanced cervical cancer (LACC) despite definitive chemo-radiotherapy, has a poor progression-free survival (PFS) and overall survival (OS).
- Trial name
- ATOMICC (NCT03833479)
- Testing
- No Further Treatment, TSR-042
- Where
- 29 sites in Spain, Turkey (Türkiye)
- Volunteers
- 134 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Esophageal Cancer, Nimotuzumab
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) who failed to induction chemo(immuno)therapy had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC.
- Conditions
- Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
- Trial name
- NCT06410651
- Testing
- Nimotuzumab with chemoradiotherapy
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Cancer
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma (ESCC). Aim to evaluate the efficacy and safety of Iparomlimab consolidation therapy following concurrent…
- Trial name
- NCT07038629
- Testing
- S1, Iparomlimab, Radiation
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Xerostomia
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect…
- Trial name
- NCT04392622
- Testing
- D-Limonene Gelcaps, Intensity modulated radiotherapy (IMRT), Cisplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Hypopharyngeal Squamous Cell Carcinoma
Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-ADC) in combination with Pucotenlimab(Anti-PD-1 Monoclonal Antibody) as neoadjuvant therapy for patients with Resectable Locally Advanced…
- Trial name
- RESERVE-HC (NCT07665190)
- Testing
- Becotatug Vedotin and Pucotenlimab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital